Developers,Name,Phase,Vaccine,Platform,N,Age (years),N_doses,Location,Location_clean,Location_status,alpha3,Latitude,Longitude,N_enrolled,Update_date,Update_link,Start_date,Primary_completion_date,Trial_number,Link,Status,Additional_links
University of Oxford/AstraZeneca,ChAdOx1-S,Phase II/III,Oxford/AstraZeneca ChAdOx1-S,Vector (non-replicating),12390,≥18,1 or 2 +/- boost,UK,UK,Active/recruiting,GBR,54,-2,Unknown,NA,NA,28/05/2020,30/09/2021,NCT04400838,https://clinicaltrials.gov/ct2/show/NCT04400838,Recruiting,NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase III,Oxford/AstraZeneca ChAdOx1-S,Vector (non-replicating),10300,≥18,1 or 2,Brazil,Brazil,Active/recruiting,BRA,-10,-55,Unknown,NA,NA,02/06/2020,30/09/2021,NCT04536051,https://clinicaltrials.gov/ct2/show/NCT04536051,Recruiting,NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase II/III,Oxford/AstraZeneca ChAdOx1-S,Vector (non-replicating),1600,≥18,2,India,India,Active/recruiting,IND,20,77,Unknown,NA,NA,24/08/2020,24/03/2021,CTRI/2020/08/027170,http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=46186&EncHid=&userName=covid-19%20vaccine,"Active, not recruiting",NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase III,Oxford/AstraZeneca ChAdOx1-S,Vector (non-replicating),32459,≥18,2,USA,USA,Active/recruiting,USA,38,-97,Unknown,NA,NA,28/08/2020,05/03/2021,NCT04516746,https://clinicaltrials.gov/ct2/show/NCT04516746,"Active, not recruiting",NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase III,Oxford/AstraZeneca ChAdOx1-S,Vector (non-replicating),32459,≥18,2,Argentina,Argentina,Active/recruiting,ARG,-34,-64,Unknown,NA,NA,28/08/2020,05/03/2021,NCT04516746,https://clinicaltrials.gov/ct2/show/NCT04516746,"Active, not recruiting",NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase III,Oxford/AstraZeneca ChAdOx1-S,Vector (non-replicating),32459,≥18,2,Chile,Chile,Active/recruiting,CHL,-30,-71,Unknown,NA,NA,28/08/2020,05/03/2021,NCT04516746,https://clinicaltrials.gov/ct2/show/NCT04516746,"Active, not recruiting",NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase III,Oxford/AstraZeneca ChAdOx1-S,Vector (non-replicating),32459,≥18,2,Colombia,Colombia,Active/recruiting,COL,4,-72,Unknown,NA,NA,28/08/2020,05/03/2021,NCT04516746,https://clinicaltrials.gov/ct2/show/NCT04516746,"Active, not recruiting",NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase III,Oxford/AstraZeneca ChAdOx1-S,Vector (non-replicating),32459,≥18,2,France,France,Active/recruiting,FRA,46,2,Unknown,NA,NA,28/08/2020,05/03/2021,NCT04516746,https://clinicaltrials.gov/ct2/show/NCT04516746,"Active, not recruiting",NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase III,Oxford/AstraZeneca ChAdOx1-S,Vector (non-replicating),32459,≥18,2,Peru,Peru,Active/recruiting,PER,-10,-76,Unknown,NA,NA,28/08/2020,05/03/2021,NCT04516746,https://clinicaltrials.gov/ct2/show/NCT04516746,"Active, not recruiting",NA
University of Oxford/AstraZeneca,ChAdOx1-S/VLA2001,Phase III,Oxford/AstraZeneca ChAdOx1-S,Vector (non-replicating),4000,≥18,2,UK (Valneva comparison),UK,Active/recruiting,GBR,54,-2,Unknown,NA,NA,26/04/2021,15/07/2021,NCT04864561,https://clinicaltrials.gov/ct2/show/NCT04864561,"Active, not recruiting",NA
University of Oxford/AstraZeneca/Beijing Institute of Biological Products/Sinopharm,ChAdOx1-S/BBIBP-CorV,Phase II/III,Oxford/AstraZeneca ChAdOx1-S,Vector (non-replicating),4000,≥18,2,Egypt (BBIBP-CorV comparison),Egypt,Active/recruiting,EGY,27,30,Unknown,NA,NA,23/02/2021,01/10/2021,NCT04885764,https://clinicaltrials.gov/ct2/show/NCT04885764,Recruiting,NA
,,,,,,,,,,,,,,,,,,,,,,
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase III,Anhui Zhifei Longcom Biopharmaceutical ZF2001,Protein subunit,29000,≥18,Unclear,China,Mainland China,Active/recruiting,CHN,35,105,Unknown,NA,NA,16/12/2020,30/04/2022,NCT04646590,https://clinicaltrials.gov/ct2/show/NCT04646590,Recruiting,NA
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase III,Anhui Zhifei Longcom Biopharmaceutical ZF2001,Protein subunit,29000,≥18,Unclear,Ecuador,Mainland China,Active/recruiting,ECU,-2,-77.5,Unknown,NA,NA,16/12/2020,30/04/2022,NCT04646590,https://clinicaltrials.gov/ct2/show/NCT04646590,Recruiting,NA
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase III,Anhui Zhifei Longcom Biopharmaceutical ZF2001,Protein subunit,29000,≥18,Unclear,Indonesia,Mainland China,Active/recruiting,IDN,-5,120,Unknown,NA,NA,16/12/2020,30/04/2022,NCT04646590,https://clinicaltrials.gov/ct2/show/NCT04646590,Recruiting,NA
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase III,Anhui Zhifei Longcom Biopharmaceutical ZF2001,Protein subunit,29000,≥18,Unclear,Pakistan,Mainland China,Active/recruiting,PAK,30,70,Unknown,NA,NA,16/12/2020,30/04/2022,NCT04646590,https://clinicaltrials.gov/ct2/show/NCT04646590,Recruiting,NA
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase III,Anhui Zhifei Longcom Biopharmaceutical ZF2001,Protein subunit,29000,≥18,Unclear,Uzbekistan,Mainland China,Active/recruiting,UZB,41,64,Unknown,NA,NA,16/12/2020,30/04/2022,NCT04646590,https://clinicaltrials.gov/ct2/show/NCT04646590,Recruiting,NA
,,,,,,,,,,,,,,,,,,,,,,
BioNTech/Pfizer/Fosun Pharma,BNT162 (b1/b2/b2SA),Phase II/III,BioNTech/Pfizer BNT162,RNA,43998,≥12,2 +/- boost,USA,USA,Active/recruiting,USA,38,-97,"46,331 (100%)",10/05/2021,https://www.pfizer.com/science/coronavirus/vaccine/about-our-landmark-trial,27/07/2020,02/11/2021,NCT04368728,https://clinicaltrials.gov/ct2/show/NCT04368728,Recruiting,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-0
BioNTech/Pfizer/Fosun Pharma,BNT162 (b1/b2/b2SA),Phase II/III,BioNTech/Pfizer BNT162,RNA,43998,≥12,2 +/- boost,Argentina,Argentina,Active/recruiting,ARG,-34,-64,"46,331 (100%)",10/05/2021,https://www.pfizer.com/science/coronavirus/vaccine/about-our-landmark-trial,27/07/2020,02/11/2021,NCT04368728,https://clinicaltrials.gov/ct2/show/NCT04368728,Recruiting,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b1/b2/b2SA),Phase II/III,BioNTech/Pfizer BNT162,RNA,43998,≥12,2 +/- boost,Brazil,Brazil,Active/recruiting,BRA,-10,-55,"46,331 (100%)",10/05/2021,https://www.pfizer.com/science/coronavirus/vaccine/about-our-landmark-trial,27/07/2020,02/11/2021,NCT04368728,https://clinicaltrials.gov/ct2/show/NCT04368728,Recruiting,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b1/b2/b2SA),Phase II/III,BioNTech/Pfizer BNT162,RNA,43998,≥12,2 +/- boost,Germany,Germany,Active/recruiting,DEU,51,9,"46,331 (100%)",10/05/2021,https://www.pfizer.com/science/coronavirus/vaccine/about-our-landmark-trial,27/07/2020,02/11/2021,NCT04368728,https://clinicaltrials.gov/ct2/show/NCT04368728,Recruiting,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b1/b2/b2SA),Phase II/III,BioNTech/Pfizer BNT162,RNA,43998,≥12,2 +/- boost,South Africa,South Africa,Active/recruiting,ZAF,-29,24,"46,331 (100%)",10/05/2021,https://www.pfizer.com/science/coronavirus/vaccine/about-our-landmark-trial,27/07/2020,02/11/2021,NCT04368728,https://clinicaltrials.gov/ct2/show/NCT04368728,Recruiting,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b1/b2/b2SA),Phase II/III,BioNTech/Pfizer BNT162,RNA,43998,≥12,2 +/- boost,Turkey,Turkey,Active/recruiting,TUR,39,35,"46,331 (100%)",10/05/2021,https://www.pfizer.com/science/coronavirus/vaccine/about-our-landmark-trial,27/07/2020,02/11/2021,NCT04368728,https://clinicaltrials.gov/ct2/show/NCT04368728,Recruiting,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2/b2.B.1.351),Phase III,BioNTech/Pfizer BNT162,RNA,1530,12–50,1 (boost) or 2,USA (lot/dose/b2.B.1.351 comparison),USA,Active/recruiting,USA,38,-97,Unknown,NA,NA,15/02/2021,22/07/2021,NCT04713553,https://clinicaltrials.gov/ct2/show/NCT04713553,Recruiting,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase I/II/III,BioNTech/Pfizer BNT162,RNA,4644,0.5–11,2,USA (children),USA,Active/recruiting,USA,38,-97,Unknown,NA,NA,24/03/2021,04/03/2022,NCT04816643,https://clinicaltrials.gov/ct2/show/NCT04816643,Recruiting,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase I/II/III,BioNTech/Pfizer BNT162,RNA,4644,0.5–11,2,Finland (children),Finland,Not yet recruiting,FIN,64,26,Unknown,NA,NA,24/03/2021,04/03/2022,NCT04816643,https://clinicaltrials.gov/ct2/show/NCT04816643,Recruiting,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase I/II/III,BioNTech/Pfizer BNT162,RNA,4644,0.5–11,2,Poland (children),Poland,Not yet recruiting,POL,52,20,Unknown,NA,NA,24/03/2021,04/03/2022,NCT04816643,https://clinicaltrials.gov/ct2/show/NCT04816643,Recruiting,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase I/II/III,BioNTech/Pfizer BNT162,RNA,4644,0.5–11,2,Spain (children),Spain,Not yet recruiting,ESP,40,-4,Unknown,NA,NA,24/03/2021,04/03/2022,NCT04816643,https://clinicaltrials.gov/ct2/show/NCT04816643,Recruiting,NA
,,,,,,,,,,,,,,,,,,,,,,
Bharat Biotech/ICMR/National Institute of Virology,COVAXIN,Phase III,Bharat Covaxin/BBV152,Inactivated,25800,≥18,2,India,India,Active/recruiting,IND,20,77,Unknown,NA,NA,16/11/2020,08/01/2021,NCT04641481,https://clinicaltrials.gov/ct2/show/NCT04641481,"Active, not recruiting",NA
,,,,,,,,,,,,,,,,,,,,,,
Wuhan Institute of Biological Products/Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase III,Beijing/Sinopharm BBIBP-CorV,Inactivated,45000,≥18,2,Bahrain,Bahrain,Active/recruiting,BHR,26,50.55,Unknown,NA,NA,16/07/2020,16/06/2021,NCT04510207,https://clinicaltrials.gov/ct2/show/NCT04510207,Recruiting,NA
Wuhan Institute of Biological Products/Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase III,Beijing/Sinopharm BBIBP-CorV,Inactivated,45000,≥18,2,Egypt,Egypt,Active/recruiting,EGY,27,30,Unknown,NA,NA,16/07/2020,16/06/2021,NCT04510207,https://clinicaltrials.gov/ct2/show/NCT04510207,Recruiting,NA
Wuhan Institute of Biological Products/Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase III,Beijing/Sinopharm BBIBP-CorV,Inactivated,45000,≥18,2,Jordan,Jordan,Active/recruiting,JOR,31,36,Unknown,NA,NA,16/07/2020,16/06/2021,NCT04510207,https://clinicaltrials.gov/ct2/show/NCT04510207,Recruiting,NA
Wuhan Institute of Biological Products/Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase III,Beijing/Sinopharm BBIBP-CorV,Inactivated,45000,≥18,2,United Arab Emirates,United Arab Emirates,Active/recruiting,ARE,24,54,Unknown,NA,NA,16/07/2020,16/06/2021,NCT04510207,https://clinicaltrials.gov/ct2/show/NCT04510207,Recruiting,NA
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase III,Beijing/Sinopharm BBIBP-CorV,Inactivated,3000,18–85,2,Argentina,Argentina,Active/recruiting,ARG,-34,-64,Unknown,NA,NA,16/09/2020,01/12/2021,NCT04560881,https://clinicaltrials.gov/ct2/show/NCT04560881,"Active, not recruiting",NA
Wuhan Institute of Biological Products/Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase III,Beijing/Sinopharm BBIBP-CorV,Inactivated,12000,≥18,2,Peru,Peru,Active/recruiting,PER,-10,-76,Unknown,NA,NA,09/09/2020,19/02/2021,NCT04612972,https://clinicaltrials.gov/ct2/show/NCT04612972,"Active, not recruiting",NA
University of Oxford/AstraZeneca/Beijing Institute of Biological Products/Sinopharm,ChAdOx1-S/BBIBP-CorV,Phase II/III,Beijing/Sinopharm BBIBP-CorV,Inactivated,4000,≥18,2,Egypt (ChAdOx1-S comparison),Egypt,Active/recruiting,EGY,27,30,Unknown,NA,NA,23/02/2021,01/10/2021,NCT04885764,https://clinicaltrials.gov/ct2/show/NCT04885764,Recruiting,NA
,,,,,,,,,,,,,,,,,,,,,,
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase III,Cansino Ad5-nCoV,Vector (non-replicating),40000,≥18,1,Argentina,Argentina,Active/recruiting,ARG,-34,-64,Unknown,NA,NA,15/09/2020,30/12/2021,NCT04526990,https://clinicaltrials.gov/ct2/show/NCT04526990,Recruiting,NA
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase III,Cansino Ad5-nCoV,Vector (non-replicating),40000,≥18,1,Chile,Chile,Active/recruiting,CHL,-30,-71,Unknown,NA,NA,15/09/2020,30/12/2021,NCT04526990,https://clinicaltrials.gov/ct2/show/NCT04526990,Recruiting,NA
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase III,Cansino Ad5-nCoV,Vector (non-replicating),40000,≥18,1,Mexico,Mexico,Active/recruiting,MEX,23,-102,Unknown,NA,NA,15/09/2020,30/12/2021,NCT04526990,https://clinicaltrials.gov/ct2/show/NCT04526990,Recruiting,NA
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase III,Cansino Ad5-nCoV,Vector (non-replicating),40000,≥18,1,Pakistan,Pakistan,Active/recruiting,PAK,30,70,Unknown,NA,NA,15/09/2020,30/12/2021,NCT04526990,https://clinicaltrials.gov/ct2/show/NCT04526990,Recruiting,NA
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase III,Cansino Ad5-nCoV,Vector (non-replicating),40000,≥18,1,Russia,Russia,Active/recruiting,RUS,60,100,Unknown,NA,NA,15/09/2020,30/12/2021,NCT04526990,https://clinicaltrials.gov/ct2/show/NCT04526990,Recruiting,NA
,,,,,,,,,,,,,,,,,,,,,,
Center for Genetic Engineering and Biotechnology,CIGB-66,Phase III,Center for Genetic Eng. and Biotech. CIGB-66,Protein subunit,48000,19–80,3,Cuba,Cuba,Not yet recruiting,CUB,21.5,-80,Unknown,NA,NA,22/03/2021,31/07/2021,IG/CIGB-66I/CVD19/2103,https://rpcec.sld.cu/en/trials/RPCEC00000359-En,Pending,NA
,,,,,,,,,,,,,,,,,,,,,,
"Institute of Medical Biology,/Chinese Academy of Medical Sciences",Inactivated vaccine,Phase III,Chinese Academy of Medical Sciences vaccine,Inactivated,34020,≥18,2,Brazil,Brazil,Active/recruiting,BRA,-10,-55,Unknown,NA,NA,28/01/2021,30/09/2021,NCT04659239,https://clinicaltrials.gov/ct2/show/NCT04659239,Enrolling by invitation,NA
"Institute of Medical Biology,/Chinese Academy of Medical Sciences",Inactivated vaccine,Phase III,Chinese Academy of Medical Sciences vaccine,Inactivated,34020,≥18,2,Malaysia,Malaysia,Active/recruiting,MYS,2.5,112.5,Unknown,NA,NA,28/01/2021,30/09/2021,NCT04659239,https://clinicaltrials.gov/ct2/show/NCT04659239,Enrolling by invitation,NA
,,,,,,,,,,,,,,,,,,,,,,
Instituto Finlay de Vacunas,FINLAY-FR-2/Soberana 02,Phase III,Instituto Finlay de Vacunas Soberana 02,Protein subunit,44010,19–80,2 or 3,Cuba,Cuba,Not yet recruiting,CUB,21.5,-80,Unknown,NA,NA,05/03/2021,07/11/2021,IFV/COR/09,https://rpcec.sld.cu/en/trials/RPCEC00000354-En,Pending,NA
,,,,,,,,,,,,,,,,,,,,,,
Clover Biopharmaceuticals Inc/GSK/Dynavax,SCB-2019,Phase II/III,Clover SCB-2019,Protein subunit,22000,≥18,2,Belgium,Belgium,Not yet recruiting,BEL,50.8333,4,Unknown,NA,NA,01/03/2021,31/07/2022,NCT04672395,https://clinicaltrials.gov/ct2/show/NCT04672395,Not yet recruiting,NA
Clover Biopharmaceuticals Inc/GSK/Dynavax,SCB-2019,Phase II/III,Clover SCB-2019,Protein subunit,22000,≥18,2,Brazil,Brazil,Not yet recruiting,BRA,-10,-55,Unknown,NA,NA,01/03/2021,31/07/2022,NCT04672395,https://clinicaltrials.gov/ct2/show/NCT04672395,Not yet recruiting,NA
Clover Biopharmaceuticals Inc/GSK/Dynavax,SCB-2019,Phase II/III,Clover SCB-2019,Protein subunit,22000,≥18,2,Colombia,Colombia,Not yet recruiting,COL,4,-72,Unknown,NA,NA,01/03/2021,31/07/2022,NCT04672395,https://clinicaltrials.gov/ct2/show/NCT04672395,Not yet recruiting,NA
Clover Biopharmaceuticals Inc/GSK/Dynavax,SCB-2019,Phase II/III,Clover SCB-2019,Protein subunit,22000,≥18,2,Dominican Republic,Dominican Republic,Not yet recruiting,DOM,19,-70.6667,Unknown,NA,NA,01/03/2021,31/07/2022,NCT04672395,https://clinicaltrials.gov/ct2/show/NCT04672395,Not yet recruiting,NA
Clover Biopharmaceuticals Inc/GSK/Dynavax,SCB-2019,Phase II/III,Clover SCB-2019,Protein subunit,22000,≥18,2,Germany,Germany,Not yet recruiting,DEU,51,9,Unknown,NA,NA,01/03/2021,31/07/2022,NCT04672395,https://clinicaltrials.gov/ct2/show/NCT04672395,Not yet recruiting,NA
Clover Biopharmaceuticals Inc/GSK/Dynavax,SCB-2019,Phase II/III,Clover SCB-2019,Protein subunit,22000,≥18,2,Nepal,Nepal,Not yet recruiting,NPL,28,84,Unknown,NA,NA,01/03/2021,31/07/2022,NCT04672395,https://clinicaltrials.gov/ct2/show/NCT04672395,Not yet recruiting,NA
Clover Biopharmaceuticals Inc/GSK/Dynavax,SCB-2019,Phase II/III,Clover SCB-2019,Protein subunit,22000,≥18,2,Panama,Panama,Not yet recruiting,PAN,9,-80,Unknown,NA,NA,01/03/2021,31/07/2022,NCT04672395,https://clinicaltrials.gov/ct2/show/NCT04672395,Not yet recruiting,NA
Clover Biopharmaceuticals Inc/GSK/Dynavax,SCB-2019,Phase II/III,Clover SCB-2019,Protein subunit,22000,≥18,2,Philippines,Philippines,Not yet recruiting,PHL,13,122,Unknown,NA,NA,01/03/2021,31/07/2022,NCT04672395,https://clinicaltrials.gov/ct2/show/NCT04672395,Not yet recruiting,NA
Clover Biopharmaceuticals Inc/GSK/Dynavax,SCB-2019,Phase II/III,Clover SCB-2019,Protein subunit,22000,≥18,2,Poland,Poland,Not yet recruiting,POL,52,20,Unknown,NA,NA,01/03/2021,31/07/2022,NCT04672395,https://clinicaltrials.gov/ct2/show/NCT04672395,Not yet recruiting,NA
Clover Biopharmaceuticals Inc/GSK/Dynavax,SCB-2019,Phase II/III,Clover SCB-2019,Protein subunit,22000,≥18,2,South Africa,South Africa,Not yet recruiting,ZAF,-29,24,Unknown,NA,NA,01/03/2021,31/07/2022,NCT04672395,https://clinicaltrials.gov/ct2/show/NCT04672395,Not yet recruiting,NA
,,,,,,,,,,,,,,,,,,,,,,
CureVac,CVnCoV,Phase II/III,CureVac CVnCoV,RNA,36500,≥18,2,Argentina,Argentina,Active/recruiting,ARG,-34,-64,Unknown,NA,NA,14/12/2020,16/04/2021,NCT04652102,https://clinicaltrials.gov/ct2/show/NCT04652102,"Active, not recruiting",NA
CureVac,CVnCoV,Phase II/III,CureVac CVnCoV,RNA,36500,≥18,2,Belgium,Belgium,Active/recruiting,BEL,50.8333,4,Unknown,NA,NA,14/12/2020,16/04/2021,NCT04652102,https://clinicaltrials.gov/ct2/show/NCT04652102,"Active, not recruiting",NA
CureVac,CVnCoV,Phase II/III,CureVac CVnCoV,RNA,36500,≥18,2,Colombia,Colombia,Active/recruiting,COL,4,-72,Unknown,NA,NA,14/12/2020,16/04/2021,NCT04652102,https://clinicaltrials.gov/ct2/show/NCT04652102,"Active, not recruiting",NA
CureVac,CVnCoV,Phase II/III,CureVac CVnCoV,RNA,36500,≥18,2,Dominican Republic,Dominican Republic,Active/recruiting,DOM,19,-70.6667,Unknown,NA,NA,14/12/2020,16/04/2021,NCT04652102,https://clinicaltrials.gov/ct2/show/NCT04652102,"Active, not recruiting",NA
CureVac,CVnCoV,Phase II/III,CureVac CVnCoV,RNA,36500,≥18,2,Germany (multisite),Germany,Active/recruiting,DEU,51,9,Unknown,NA,NA,14/12/2020,16/04/2021,NCT04652102,https://clinicaltrials.gov/ct2/show/NCT04652102,"Active, not recruiting",NA
CureVac,CVnCoV,Phase II/III,CureVac CVnCoV,RNA,36500,≥18,2,Mexico,Mexico,Active/recruiting,MEX,23,-102,Unknown,NA,NA,14/12/2020,16/04/2021,NCT04652102,https://clinicaltrials.gov/ct2/show/NCT04652102,"Active, not recruiting",NA
CureVac,CVnCoV,Phase II/III,CureVac CVnCoV,RNA,36500,≥18,2,Netherlands,Netherlands,Active/recruiting,NLD,52.5,5.75,Unknown,NA,NA,14/12/2020,16/04/2021,NCT04652102,https://clinicaltrials.gov/ct2/show/NCT04652102,"Active, not recruiting",NA
CureVac,CVnCoV,Phase II/III,CureVac CVnCoV,RNA,36500,≥18,2,Panama,Panama,Active/recruiting,PAN,9,-80,Unknown,NA,NA,14/12/2020,16/04/2021,NCT04652102,https://clinicaltrials.gov/ct2/show/NCT04652102,"Active, not recruiting",NA
CureVac,CVnCoV,Phase II/III,CureVac CVnCoV,RNA,36500,≥18,2,Peru,Peru,Active/recruiting,PER,-10,-76,Unknown,NA,NA,14/12/2020,16/04/2021,NCT04652102,https://clinicaltrials.gov/ct2/show/NCT04652102,"Active, not recruiting",NA
CureVac,CVnCoV,Phase II/III,CureVac CVnCoV,RNA,36500,≥18,2,Spain,Spain,Active/recruiting,ESP,40,-4,Unknown,NA,NA,14/12/2020,16/04/2021,NCT04652102,https://clinicaltrials.gov/ct2/show/NCT04652102,"Active, not recruiting",NA
CureVac,CVnCoV,Phase III,CureVac CVnCoV,RNA,2360,≥18,2,Germany,Germany,Active/recruiting,DEU,51,9,Unknown,NA,NA,23/12/2020,30/06/2021,NCT04674189,https://clinicaltrials.gov/ct2/show/NCT04674189,"Active, not recruiting",NA
CureVac,CVnCoV,Phase III,CureVac CVnCoV,RNA,1000,≥60,2,Argentina (≥60s),Argentina,Not yet recruiting,ARG,-34,-64,Unknown,NA,NA,10/05/2021,27/09/2021,NCT04848467,https://clinicaltrials.gov/ct2/show/NCT04848467,Not yet recruiting,NA
CureVac,CVnCoV,Phase III,CureVac CVnCoV,RNA,1000,≥60,2,Colombia (≥60s),Colombia,Not yet recruiting,COL,4,-72,Unknown,NA,NA,10/05/2021,27/09/2021,NCT04848467,https://clinicaltrials.gov/ct2/show/NCT04848467,Not yet recruiting,NA
CureVac,CVnCoV,Phase III,CureVac CVnCoV,RNA,1000,≥60,2,Peru (≥60s),Peru,Not yet recruiting,PER,-10,-76,Unknown,NA,NA,10/05/2021,27/09/2021,NCT04848467,https://clinicaltrials.gov/ct2/show/NCT04848467,Not yet recruiting,NA
CureVac,CVnCoV,Phase III,CureVac CVnCoV,RNA,1200,≥18,2,Belgium (comorbidities),Belgium,Active/recruiting,BEL,50.8333,4,Unknown,NA,NA,22/04/2021,15/09/2021,NCT04860258,https://clinicaltrials.gov/ct2/show/NCT04860258,Recruiting,NA
,,,,,,,,,,,,,,,,,,,,,,
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase III,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),33758,≥18,2,Russia,Russia,Active/recruiting,RUS,60,100,Unknown,NA,NA,07/09/2020,01/05/2021,NCT04530396,https://clinicaltrials.gov/ct2/show/NCT04530396,"Active, not recruiting",NA
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase III,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),2000,≥18,2,Venezuela,Venezuela,Not yet recruiting,VEN,8,-66,Unknown,NA,NA,01/11/2020,31/10/2021,NCT04642339,https://clinicaltrials.gov/ct2/show/NCT04642339,Not yet recruiting,NA
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase II/III,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),1600,≥18,2,India,India,Active/recruiting,IND,20,77,Unknown,NA,NA,30/11/2020,31/08/2021,NCT04640233,https://clinicaltrials.gov/ct2/show/NCT04640233,"Active, not recruiting",NA
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase II/III,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),1000,≥18,2,United Arab Emirates,United Arab Emirates,Not yet recruiting,ARE,24,54,Unknown,NA,NA,01/12/2020,31/08/2021,NCT04656613,https://clinicaltrials.gov/ct2/show/NCT04656613,Not yet recruiting,NA
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase III,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),6000,≥18,1,Russia (Sputnik-Light),Russia,Active/recruiting,RUS,60,100,Unknown,NA,NA,19/02/2021,31/12/2021,NCT04741061,https://clinicaltrials.gov/ct2/show/NCT04741061,Recruiting,NA
,,,,,,,,,,,,,,,,,,,,,,
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),44325,≥18,1,USA (1-dose),USA,Active/recruiting,USA,38,-97,Unknown,NA,NA,07/09/2020,22/01/2021,NCT04505722,https://clinicaltrials.gov/ct2/show/NCT04505722,"Active, not recruiting",NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),44325,≥18,1,Argentina (1-dose),Argentina,Active/recruiting,ARG,-34,-64,Unknown,NA,NA,07/09/2020,22/01/2021,NCT04505722,https://clinicaltrials.gov/ct2/show/NCT04505722,"Active, not recruiting",NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),44325,≥18,1,Brazil (1-dose),Brazil,Active/recruiting,BRA,-10,-55,Unknown,NA,NA,07/09/2020,22/01/2021,NCT04505722,https://clinicaltrials.gov/ct2/show/NCT04505722,"Active, not recruiting",NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),44325,≥18,1,Chile (1-dose),Chile,Active/recruiting,CHL,-30,-71,Unknown,NA,NA,07/09/2020,22/01/2021,NCT04505722,https://clinicaltrials.gov/ct2/show/NCT04505722,"Active, not recruiting",NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),44325,≥18,1,Colombia (1-dose),Colombia,Active/recruiting,COL,4,-72,Unknown,NA,NA,07/09/2020,22/01/2021,NCT04505722,https://clinicaltrials.gov/ct2/show/NCT04505722,"Active, not recruiting",NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),44325,≥18,1,Mexico (1-dose),Mexico,Active/recruiting,MEX,23,-102,Unknown,NA,NA,07/09/2020,22/01/2021,NCT04505722,https://clinicaltrials.gov/ct2/show/NCT04505722,"Active, not recruiting",NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),44325,≥18,1,Peru (1-dose),Peru,Active/recruiting,PER,-10,-76,Unknown,NA,NA,07/09/2020,22/01/2021,NCT04505722,https://clinicaltrials.gov/ct2/show/NCT04505722,"Active, not recruiting",NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),44325,≥18,1,South Africa (1-dose),South Africa,Active/recruiting,ZAF,-29,24,Unknown,NA,NA,07/09/2020,22/01/2021,NCT04505722,https://clinicaltrials.gov/ct2/show/NCT04505722,"Active, not recruiting",NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),31836,≥18,2,USA (2-dose),USA,Active/recruiting,USA,38,-97,Unknown,NA,NA,16/11/2020,31/05/2022,NCT04614948,https://clinicaltrials.gov/ct2/show/NCT04614948,"Active, not recruiting",NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),31836,≥18,2,Belgium (2-dose),Belgium,Active/recruiting,BEL,50.8333,4,Unknown,NA,NA,16/11/2020,31/05/2022,NCT04614948,https://clinicaltrials.gov/ct2/show/NCT04614948,"Active, not recruiting",NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),31836,≥18,2,Brazil (2-dose),Brazil,Active/recruiting,BRA,-10,-55,Unknown,NA,NA,16/11/2020,31/05/2022,NCT04614948,https://clinicaltrials.gov/ct2/show/NCT04614948,"Active, not recruiting",NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),31836,≥18,2,Colombia (2-dose),Colombia,Active/recruiting,COL,4,-72,Unknown,NA,NA,16/11/2020,31/05/2022,NCT04614948,https://clinicaltrials.gov/ct2/show/NCT04614948,"Active, not recruiting",NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),31836,≥18,2,France (2-dose),France,Active/recruiting,FRA,46,2,Unknown,NA,NA,16/11/2020,31/05/2022,NCT04614948,https://clinicaltrials.gov/ct2/show/NCT04614948,"Active, not recruiting",NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),31836,≥18,2,Germany (2-dose),Germany,Active/recruiting,DEU,51,9,Unknown,NA,NA,16/11/2020,31/05/2022,NCT04614948,https://clinicaltrials.gov/ct2/show/NCT04614948,"Active, not recruiting",NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),31836,≥18,2,Philippines (2-dose),Philippines,Active/recruiting,PHL,13,122,Unknown,NA,NA,16/11/2020,31/05/2022,NCT04614948,https://clinicaltrials.gov/ct2/show/NCT04614948,"Active, not recruiting",NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),31836,≥18,2,South Africa (2-dose),South Africa,Active/recruiting,ZAF,-29,24,Unknown,NA,NA,16/11/2020,31/05/2022,NCT04614948,https://clinicaltrials.gov/ct2/show/NCT04614948,"Active, not recruiting",NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),31836,≥18,2,Spain (2-dose),Spain,Active/recruiting,ESP,40,-4,Unknown,NA,NA,16/11/2020,31/05/2022,NCT04614948,https://clinicaltrials.gov/ct2/show/NCT04614948,"Active, not recruiting",NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),31836,≥18,2,UK (2-dose),UK,Active/recruiting,GBR,54,-2,Unknown,NA,NA,16/11/2020,31/05/2022,NCT04614948,https://clinicaltrials.gov/ct2/show/NCT04614948,"Active, not recruiting",NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),500000,≥18,1,"South Africa (1-dose, healthcare workers)",South Africa,Active/recruiting,ZAF,-29,24,Unknown,NA,NA,18/02/2021,31/03/2022,NCT04838795,https://clinicaltrials.gov/ct2/show/NCT04838795,Recruiting,NA
,,,,,,,,,,,,,,,,,,,,,,
Medicago Inc,CoVLP,Phase II/III,Medicago CoVLP,Virus-like particle,30918,≥18,2,USA,USA,Active/recruiting,USA,38,-97,Unknown,NA,NA,19/11/2020,31/12/2021,NCT04636697,https://clinicaltrials.gov/ct2/show/NCT04636697,Recruiting,NA
Medicago Inc,CoVLP,Phase II/III,Medicago CoVLP,Virus-like particle,30918,≥18,2,Canada,Canada,Active/recruiting,CAN,60,-95,Unknown,NA,NA,19/11/2020,31/12/2021,NCT04636697,https://clinicaltrials.gov/ct2/show/NCT04636697,Recruiting,NA
Medicago Inc,CoVLP,Phase II/III,Medicago CoVLP,Virus-like particle,30918,≥18,2,UK,UK,Active/recruiting,GBR,54,-2,Unknown,NA,NA,19/11/2020,31/12/2021,NCT04636697,https://clinicaltrials.gov/ct2/show/NCT04636697,Recruiting,NA
,,,,,,,,,,,,,,,,,,,,,,
Moderna/NIAID,mRNA-1273,Phase III,Moderna mRNA-1273,RNA,30420,≥18,2,USA (adults),USA,Active/recruiting,USA,38,-97,"30,000 (100%)",22/10/2020,https://www.modernatx.com/cove-study,27/07/2020,27/10/2022,NCT04470427,https://clinicaltrials.gov/ct2/show/NCT04470427,"Active, not recruiting",NA
Moderna/NIAID,mRNA-1273,Phase II/III,Moderna mRNA-1273,RNA,3732,12–17,2,USA (adolescents),USA,Active/recruiting,USA,38,-97,Unknown,NA,NA,09/12/2020,30/06/2022,NCT04649151,https://clinicaltrials.gov/ct2/show/NCT04649151,"Active, not recruiting",NA
Moderna/NIAID,mRNA-1273,Phase III,Moderna mRNA-1273,RNA,7050,0.5–11,2,USA (children),USA,Active/recruiting,USA,38,-97,Unknown,NA,NA,15/03/2021,12/06/2023,NCT04796896,https://clinicaltrials.gov/ct2/show/NCT04796896,Recruiting,NA
Moderna/NIAID,mRNA-1273,Phase III,Moderna mRNA-1273,RNA,37500,18–26,2,USA (student transmission),USA,Active/recruiting,USA,38,-97,Unknown,NA,NA,24/03/2021,22/12/2021,NCT04811664,https://clinicaltrials.gov/ct2/show/NCT04811664,Recruiting,NA
,,,,,,,,,,,,,,,,,,,,,,
Nanogen Biopharmaceutical,Nanocovax,Phase III,Nanogen Nanocovax,Protein subunit,13000,≥18,2,Vietnam,Vietnam,Active/recruiting,VNM,16,106,Unknown,NA,NA,07/06/2021,07/07/2022,NCT04922788,https://clinicaltrials.gov/ct2/show/NCT04922788,Recruiting,NA
,,,,,,,,,,,,,,,,,,,,,,
Novavax,NVX-CoV2373,Phase III,Novavax NVX-CoV2373,Protein subunit,15000,18–84,2,UK,UK,Active/recruiting,GBR,54,-2,Unknown,NA,NA,28/09/2020,31/01/2021,NCT04583995,https://clinicaltrials.gov/ct2/show/NCT04583995,Recruiting,NA
Novavax,NVX-CoV2373,Phase III,Novavax NVX-CoV2373,Protein subunit,33000,≥12,2,USA,USA,Active/recruiting,USA,38,-97,Unknown,NA,NA,27/12/2020,30/06/2021,NCT04611802,https://clinicaltrials.gov/ct2/show/NCT04611802,Recruiting,NA
Novavax,NVX-CoV2373,Phase III,Novavax NVX-CoV2373,Protein subunit,33000,≥12,2,Mexico,Mexico,Active/recruiting,MEX,23,-102,Unknown,NA,NA,27/12/2020,30/06/2021,NCT04611802,https://clinicaltrials.gov/ct2/show/NCT04611802,Recruiting,NA
Novavax,NVX-CoV2373,Phase III,Novavax NVX-CoV2373,Protein subunit,33000,≥12,2,Puerto Rico,Puerto Rico,Active/recruiting,PRI,18.25,-66.5,Unknown,NA,NA,27/12/2020,30/06/2021,NCT04611802,https://clinicaltrials.gov/ct2/show/NCT04611802,Recruiting,NA
,,,,,,,,,,,,,,,,,,,,,,
ReiThera/Leukocare/Univercells,GRAd-COV2,Phase II/III,ReiThera GRAd-COV2,Vector (non-replicating),10300,≥18,1 or 2,Italy,Italy,Active/recruiting,ITA,42.8333,12.8333,Unknown,NA,NA,15/03/2021,30/05/2021,NCT04791423,https://clinicaltrials.gov/ct2/show/NCT04791423,"Active, not recruiting",NA
,,,,,,,,,,,,,,,,,,,,,,
Research Institute for Biological Safety Problems,QazCovid-in,Phase III,Research Institute for Biological Safety Problems QazCovid-in,Inactivated,3000,≥18,2,Kazakhstan,Kazakhstan,Active/recruiting,KAZ,48,68,Unknown,NA,NA,25/12/2020,20/07/2021,NCT04691908,https://clinicaltrials.gov/ct2/show/NCT04691908,"Active, not recruiting",NA
,,,,,,,,,,,,,,,,,,,,,,
Sanofi Pasteur/GSK,CoV2 preS dTM,Phase III,Sanofi/GSK CoV2 preS dTM,Protein subunit,37430,≥18,2,USA,USA,Active/recruiting,USA,38,-97,Unknown,NA,NA,26/05/2021,13/01/2023,NCT04904549,https://clinicaltrials.gov/ct2/show/NCT04904549,Recruiting,NA
,,,,,,,,,,,,,,,,,,,,,,
Shifa Pharmed,Inactivated vaccine,Phase II/III,Shifa Pharmed vaccine,Inactivated,20280,18–75,2,Iran,Iran,Active/recruiting,IRN,32,53,Unknown,NA,NA,14/03/2021,Pending,IRCT20201202049567N3,https://en.irct.ir/trial/54881,Recruiting,NA
,,,,,,,,,,,,,,,,,,,,,,
Sinovac,CoronaVac,Phase III,Sinovac CoronaVac,Inactivated,12688,≥18,2,Brazil (phase III),Brazil,Active/recruiting,BRA,-10,-55,Unknown,NA,NA,21/07/2020,17/12/2020,NCT04456595,https://clinicaltrials.gov/ct2/show/NCT04456595,"Active, not recruiting",NA
Sinovac,CoronaVac,Phase III,Sinovac CoronaVac,Inactivated,1620,18–59,2,Indonesia,Indonesia,Active/recruiting,IDN,-5,120,Unknown,NA,NA,10/08/2020,09/01/2021,NCT04508075,https://clinicaltrials.gov/ct2/show/NCT04508075,"Active, not recruiting",NA
Sinovac,CoronaVac,Phase III,Sinovac CoronaVac,Inactivated,13000,18–59,2,Turkey,Turkey,Active/recruiting,TUR,39,35,Unknown,NA,NA,14/09/2020,15/02/2021,NCT04582344,https://clinicaltrials.gov/ct2/show/NCT04582344,Recruiting,NA
Sinovac,CoronaVac,Phase III,Sinovac CoronaVac,Inactivated,1040,≥18,2,China,Mainland China,Active/recruiting,CHN,35,105,Unknown,NA,NA,31/10/2020,28/11/2020,NCT04617483,https://clinicaltrials.gov/ct2/show/NCT04617483,Recruiting,NA
Sinovac,CoronaVac,Phase III,Sinovac CoronaVac,Inactivated,2300,≥18,2,Chile,Chile,Active/recruiting,CHL,-30,-71,Unknown,NA,NA,27/11/2020,31/01/2022,NCT04651790,https://clinicaltrials.gov/ct2/show/NCT04651790,Recruiting,NA
Sinovac,CoronaVac,Phase IV,Sinovac CoronaVac,Inactivated,30000,≥18,2,Brazil (phase IV),Brazil,Active/recruiting,BRA,-10,-55,Unknown,NA,NA,17/02/2021,31/05/2021,NCT04747821,https://clinicaltrials.gov/ct2/show/NCT04747821,Enrolling by invitation,NA
,,,,,,,,,,,,,,,,,,,,,,
Valneva/Dynavax,ChAdOx1-S/VLA2001,Phase III,Valneva VLA2001,Inactivated,4000,≥18,2,UK,UK,Active/recruiting,GBR,54,-2,Unknown,NA,NA,26/04/2021,15/07/2021,NCT04864561,https://clinicaltrials.gov/ct2/show/NCT04864561,"Active, not recruiting",NA
,,,,,,,,,,,,,,,,,,,,,,
Vector Institute (peptide),EpiVacCorona,Phase III,Vector Institute EpiVacCorona,Protein subunit,3000,≥18,2,Russia,Russia,Active/recruiting,RUS,60,100,Unknown,NA,NA,18/11/2020,31/08/2021,NCT04780035,https://clinicaltrials.gov/ct2/show/NCT04780035,"Active, not recruiting",NA
,,,,,,,,,,,,,,,,,,,,,,
Wuhan Institute of Biological Products/Beijing Institute of Biological Products/Sinopharm,WIBP vaccine,Phase III,Wuhan/Sinopharm vaccine,Inactivated,45000,≥18,2,Bahrain,Bahrain,Active/recruiting,BHR,26,50.55,Unknown,NA,NA,16/07/2020,16/03/2021,NCT04510207,https://clinicaltrials.gov/ct2/show/NCT04510207,Recruiting,NA
Wuhan Institute of Biological Products/Beijing Institute of Biological Products/Sinopharm,WIBP vaccine,Phase III,Wuhan/Sinopharm vaccine,Inactivated,45000,≥18,2,Egypt,Egypt,Active/recruiting,EGY,27,30,Unknown,NA,NA,16/07/2020,16/03/2021,NCT04510207,https://clinicaltrials.gov/ct2/show/NCT04510207,Recruiting,NA
Wuhan Institute of Biological Products/Beijing Institute of Biological Products/Sinopharm,WIBP vaccine,Phase III,Wuhan/Sinopharm vaccine,Inactivated,45000,≥18,2,Jordan,Jordan,Active/recruiting,JOR,31,36,Unknown,NA,NA,16/07/2020,16/03/2021,NCT04510207,https://clinicaltrials.gov/ct2/show/NCT04510207,Recruiting,NA
Wuhan Institute of Biological Products/Beijing Institute of Biological Products/Sinopharm,WIBP vaccine,Phase III,Wuhan/Sinopharm vaccine,Inactivated,45000,≥18,2,United Arab Emirates,United Arab Emirates,Active/recruiting,ARE,24,54,Unknown,NA,NA,16/07/2020,16/03/2021,NCT04510207,https://clinicaltrials.gov/ct2/show/NCT04510207,Recruiting,NA
Wuhan Institute of Biological Products/Beijing Institute of Biological Products/Sinopharm,WIBP vaccine,Phase III,Wuhan/Sinopharm vaccine,Inactivated,12000,≥18,2,Peru,Peru,Active/recruiting,PER,-10,-76,Unknown,NA,NA,09/09/2020,19/02/2021,NCT04612972,https://clinicaltrials.gov/ct2/show/NCT04612972,"Active, not recruiting",NA